Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2011-02-18 Director's Dealing
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2011-02-18 English
Regulatory Filings 2011
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It indicates that the company, NanoViricides, Inc., could not file its periodic report (in this case, a Form 10-Q for the period ended December 31, 2010) on time due to inability to compile necessary financial information. The form requests an extension and explains the reason for the delay. The document does not contain actual financial statements or substantive financial data but is rather a regulatory notification about the delay in filing. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document and not the report itself.
2011-02-14 English
NANOVIRICIDES 8-K 12-22-2010
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a financing transaction involving the purchase of Series B Convertible Preferred Stock, details of conversion rights, dividend terms, and placement agent fees. It also references a press release attached as Exhibit 99.1. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, proxy, or governance document. It is a regulatory filing announcing a capital financing event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6484 characters) supports it being a substantive filing rather than a brief announcement or certification.
2010-12-22 English
NANOVIRICIDES 424B3 12-20-2010
Capital/Financing Update Classification · 95% confidence The document is a Prospectus Supplement filed pursuant to Rule 424(b)(3), which is a regulatory filing related to securities offerings. It details the terms of a follow-on closing involving convertible preferred stock and common stock, including pricing, conversion terms, dividends, and placement agent fees. The document is not a full financial report, earnings release, or management discussion, but rather a detailed update on a capital raising transaction. Given the content and the form type (424B3), this fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive details about the financing terms, so it is not merely an announcement but a detailed supplement to a prospectus. Therefore, the appropriate classification is CAP with high confidence.
2010-12-20 English
NANOVIRICIDES, INC. S-8 12-10-2010
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by NanoViricides, Inc. on December 10, 2010. It relates to the registration of securities (common stock) to be issued pursuant to a consulting agreement. The document includes sections typical of registration statements such as plan information, incorporation by reference of prior filings (including 10-K and 10-Q), indemnification provisions, and exhibits. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or management discussion. It is a capital market filing related to securities registration under the Securities Act of 1933. The closest fitting category from the provided list is "Capital/Financing Update (CAP)" since it concerns registration of securities for issuance and related capital structure matters. The document length (15,000 characters) and content confirm it is the registration statement itself, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2010-12-10 English
NANOVIRICIDES, INC 10-Q 9-30-2010
Interim / Quarterly Report Q1 2011
2010-11-18 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.